太极集团技术资本配置案例分析

发布时间：2018-03-31 08:22

本文选题：太极集团　切入点：技术资本　出处：《中国海洋大学》2013年硕士论文

【摘要】：最近几年,国外品牌纷纷关闭在华工厂。表面原因是我国人力资本价格上涨过快,其实质是我国企业缺少自主技术,技术资产薄弱,企业技术进步缓慢,生产方式落后。纵观我国近十年的研发投入,逐年快速增长,并在2011年位居世界第三,但高研发投入没有获得应有的效益。世界经济正在经历新一轮的社会专业分工。高新技术的快速发展和生产模块化商业模式的出现,使西方发达国家解决了制造环节的外包问题,产品加工制造环节不再需要投入大量人力资源。这就对我国的经济发展提出了新的挑战。以案例分析为研究方法,以著名医药制造企业集团太极实业集团为实例,研究我国医药企业的技术资本配置结构及其效率,以内部与外部两个切入点,发现现存问题、总结原因与经验,提出对策。研究分析发现,医药行业技术资本投入不高,研发不连贯十分明显,资源整合与利用效率比较低下,资产负债率较高,货币资本浪费严重。这说明,各种资本之间存在着内在联系,技术离不开人、财、物的支撑；当企业的技术资本内部以及与外部的传统资本之间相互保持一定比例时,才能够发挥每一种资本的最大效用。本文的主要结构包括五个部分。其一,绪论部分,介绍研究背景、研究的问题及意义和拟采用的研究方法与思路。其二,文献部分,将之前学者的相关研究整合归类,从自主研发和外部引进两个方面梳理技术资本及其配置的相关文献。其三,案例介绍,简短介绍太极集团,指出案例的主要问题,并对之后的案例分析做出研究假设与说明。其四,案例分析,运用资源禀赋结构和要素资本理论,讨论企业资本的相互配置问题。这一章是论文的主体内容,也是本文理论与实际相结合的主要部分。论文从财务数据和外部环境出发,对太极集团的技术资本进行内部测算与分析,然后将其与传统资本配置予以估算,并与同业主要企业对比,找出症结所在,再从外部环境思考与技术资本相关的战略决策。其五,结论和建议。研究表明,太极集团整体的技术资本的相对值还是处于行业的领先水平,包括所拥有的专利、专有技术,旗下西南药业是我国首批十家农村基本用药定点生产企业,桐君阁则是老字号的大药房,集团优势明显,在研发、生产和销售上都有上市公司。本文认为,医药企业应结合自身,从以技术引进与自主研发相结合逐步过渡到自主研发,在具体确定配置比例时,不能盲目按照本文得出的比例,更需要结合环境和自身的技术实际进行取舍；当然,本文因为数据处理及企业年报披露有限等因素,在分析时也存在些许不足,希望能在今后的研究中加以改进。
[Abstract]:In recent years, foreign brands have closed factories in China in succession. The apparent reason is that the price of human capital in China has risen too fast. In essence, Chinese enterprises lack independent technology, have weak technical assets, and slow technological progress. Looking at our country's R & D investment in the past ten years, it has increased rapidly year by year and ranked third in the world in 2011. The world economy is experiencing a new round of social and professional division of labor, the rapid development of high and new technology and the emergence of a modular business model for production. The western developed countries have solved the outsourcing problem of manufacturing links, and the process and manufacturing of products no longer need to invest a large number of human resources, which poses a new challenge to the economic development of our country. Taking the case analysis as the research method, taking Taiji Industrial Group, a famous pharmaceutical manufacturing enterprise group, as an example, this paper studies the configuration structure and efficiency of the technical capital of Chinese pharmaceutical enterprises, and finds out the existing problems through two entry points, internal and external. The reasons and experiences are summarized, and the countermeasures are put forward. The research and analysis shows that the investment of technical capital is not high, the R & D is incoherent, the efficiency of resource integration and utilization is low, and the ratio of assets and liabilities is high. The waste of money capital is serious. This shows that there are internal relations between various kinds of capital, technology can not be separated from the support of people, money, and things; when the technological capital of an enterprise keeps a certain proportion within and between the traditional capital of the enterprise and the external capital, In order to give full play to the maximum utility of each type of capital. The main structure of this paper includes five parts. First, the introduction part, introduces the research background, the research question and the significance, and the research method and the train of thought to adopt, second, the literature part, classifies the previous scholars' related research, From two aspects of independent research and development and external introduction of technology capital and the introduction of related literature. Third, case introduction, a brief introduction to the Taiji Group, pointing out the main problems of the case. Fourth, case analysis, using the theory of resource endowment structure and factor capital, to discuss the mutual allocation of enterprise capital. This chapter is the main content of the paper. It is also the main part of the combination of theory and practice in this paper. Based on the financial data and external environment, the paper calculates and analyzes the technical capital of Taiji Group internally, and then estimates it with the traditional capital allocation. And compared with the major enterprises in the same industry, find out the crux of the problem, and then consider the strategic decisions related to technology capital from the external environment. Fifth, conclusions and recommendations. The relative value of the overall technical capital of Taiji Group is still in the leading level of the industry, including the patents and proprietary technology that it owns. Its Southwest Pharmaceutical Industry is the first batch of 10 basic rural drug manufacturers in China. Tong Junge is a big pharmacy with an old name. The group has obvious advantages, and there are listed companies in R & D, production and sales. This paper holds that pharmaceutical enterprises should gradually transition from technology introduction and independent R & D to independent R & D in combination with themselves. In determining the specific allocation ratio, we should not blindly follow the proportion obtained in this paper, but also need to combine the environment and the actual technology of our own to make a choice. Of course, because of the limited data processing and the disclosure of the annual report of the enterprise, and other factors, In the analysis, there are some shortcomings, hope to be improved in the future research.
【学位授予单位】：中国海洋大学
【学位级别】：硕士
【学位授予年份】：2013
【分类号】：F426.72;F275

【参考文献】